[]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : A single injection of THR-687 was reported safe and well-tolerated, showing a very encouraging efficacy signal. A clear dose response was seen with the greatest positive effect on BCVA and Central Subfield Thickness (CST) with the highest dose of THR-687...

                          Product Name : THR-687

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 06, 2021

                          Lead Product(s) : THR-687

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : A single injection of THR-687 was reported safe and well-tolerated, showing a very encouraging efficacy signal. This activity was maintained with a mean BCVA improvement of 8.3 letters at Month 3 following a single injection of THR-687.

                          Product Name : THR-687

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 06, 2021

                          Lead Product(s) : THR-687

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : THR-687 is a potential best-in-class small molecule pan-RGD integrin antagonist being developed to treat DME holding potential of becoming the standard of care for DME patients.

                          Product Name : THR-687

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 11, 2020

                          Lead Product(s) : THR-687

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : THR-687 is expected to enter a Phase 2 clinical trial in H2 2020. Positive topline results in a Phase 1 clinical study assessing it as a treatment for DME were announced in January 2020.

                          Product Name : THR-687

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 02, 2020

                          Lead Product(s) : THR-687

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank